Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

The Association of the British Pharmaceutical Industry (ABPI) reinstated Novo Nordisk’s membership in the group. 1 The ...

As China embarks on its three-year "weight management" campaign, Novo Nordisk has stepped forward with its powerful tools to ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its ...